Evidence-first longevity reporting
sixty-six source-reviewed stories explain what human studies, early trials, biomarkers and laboratory research can—and cannot—tell us about healthier aging.
Browse all storiesHealth & function · composite endpoints
A later analysis combined five very different first events. Aspirin and placebo rates were nearly identical—but the way the endpoint was built matters as much as the result.
Read the analysis
Essential evergreen guide
Start with the foundations before the hacks. See what human evidence supports—and where claims about slower aging or added lifespan get ahead of the science.
Original AI-assisted editorial illustration · not scientific evidence
Read all 10 evidence-first foundations
Named human authorship
Meet the author responsible for MoreYears.news sourcing, evidence boundaries, and published articles.
Latest stories
Each story names the studied population, outcome, limits, safety context and sources—without turning a promising signal into a longevity promise.
Health & function
A result makes sense only beside the question fixed before the data, the people actually analyzed and the uncertainty around the estimate.
Methods guidance with bounded examples from two human randomized trialsRead the explainerDrugs & supplements
In selected healthy Japanese adults age 65 or older, high-dose NMN produced a large biochemical change. The registered hearing outcome and measured physical function did not improve.
Human biomarkers and function · small 24-week randomized trialRead the analysisHealth & function
Physical features, accumulated deficits and performance tasks measure different inputs. Learn what a changed frailty score can and cannot establish.
Human measurement methods · historical observational validation, with consensus and molecular contextRead the explainer
Everyday foundations
In 31 older adults with frailty or pre-frailty, low-methoxy pectin did not change the inflammatory outcomes the paper defined as primary. Secondary and exploratory signals remain preliminary.
Human frailty/pre-frailty · small randomized four-week nutrition pilotRead the story
Everyday foundations
A four-week crossover trial found no detectable average increase in fasting immune-cell autophagic flux. It did not test other tissues, older adults, healthspan or lifespan.
Human blood-cell autophagic flux · small randomized crossover nutrition trialRead the story
Health & function
Fifteen randomized studies measured intrinsic capacity, quality of life or other multidimensional scores. Their results could be described study by study—not combined into extra healthy years or a treatment ranking.
Human multidimensional function and well-being · systematic review of randomized trialsRead the storyExplore by topic
Plain-language categories organize the reporting. They do not rate an intervention or imply that every topic has equally mature evidence.
New to MoreYears?
Choose an introduction or intervention path—or begin with heart health, cognition, or staying strong and independent. Every step explains why it follows.
Learn
Short guides explain evidence maturity, clinical trials and biomarkers. Editorial standards and the development record remain available in the trust links below.